Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 49

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 49
---
 notes to consolidated financial statements.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  7

PACIRA BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)  (In thousands)(Unaudited)Nine Months EndedSeptember 30,20252024Supplemental cash flow information: Cash paid for interest$10,390 $10,191 Net cash paid for income taxes$8,944 $9,575 Non-cash investing and financing activities:  Fixed assets included in accounts payable and accrued liabilities$1,116 $415 Excise tax on share repurchases included in accrued liabilities$341 $121 

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  8

PACIRA BIOSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1—DESCRIPTION OF BUSINESS

Pacira BioSciences, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) deliver innovative, non-opioid pain therapies to transform the lives of patients. The Company’s long-acting, local analgesic, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company’s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. EXPAREL is currently indicated to produce postsurgical local analgesia via infiltration in patients aged six years and older, and postsurgical regional analgesia via an interscalene brachial plexus block in adults, a sciatic nerve block in the popliteal fossa in adults, and an adductor canal block in adults for postsurgical pain management (the safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks other than an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa